228 related articles for article (PubMed ID: 26603258)
1. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
Munster P; Aggarwal R; Hong D; Schellens JH; van der Noll R; Specht J; Witteveen PO; Werner TL; Dees EC; Bergsland E; Agarwal N; Kleha JF; Durante M; Adams L; Smith DA; Lampkin TA; Morris SR; Kurzrock R
Clin Cancer Res; 2016 Apr; 22(8):1932-9. PubMed ID: 26603258
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
3. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
[TBL] [Abstract][Full Text] [Related]
4. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden S; Omlin A; Josephs D; Stavraka C; Zivi A; Pinato DJ; Anthoney A; Decordova S; Swales K; Riisnaes R; Pope L; Noguchi K; Shiokawa R; Inatani M; Prince J; Jones K; Twelves C; Spicer J; Banerji U
Clin Cancer Res; 2014 Dec; 20(23):5908-17. PubMed ID: 25231405
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
[TBL] [Abstract][Full Text] [Related]
6. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
7. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
9. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D
Invest New Drugs; 2019 Apr; 37(2):271-281. PubMed ID: 30073466
[TBL] [Abstract][Full Text] [Related]
10. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
12. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
Molife LR; Dean EJ; Blanco-Codesido M; Krebs MG; Brunetto AT; Greystoke AP; Daniele G; Lee L; Kuznetsov G; Myint KT; Wood K; de Las Heras B; Ranson MR
Clin Cancer Res; 2014 Dec; 20(24):6284-94. PubMed ID: 25278451
[TBL] [Abstract][Full Text] [Related]
13. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
14. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
15. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
16. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
[TBL] [Abstract][Full Text] [Related]
20. A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
Juric D; de Bono JS; LoRusso PM; Nemunaitis J; Heath EI; Kwak EL; Macarulla Mercadé T; Geuna E; Jose de Miguel-Luken M; Patel C; Kuida K; Sankoh S; Westin EH; Zohren F; Shou Y; Tabernero J
Clin Cancer Res; 2017 Sep; 23(17):5015-5023. PubMed ID: 28490463
[No Abstract] [Full Text] [Related]
[Next] [New Search]
